Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Serial cross-sectional estimation of vaccine and infection-induced SARS-CoV-2 sero-prevalence in children and adults, British Columbia, Canada: March 2020 to August 2022

“…The for Abbott-NP [17][18][19][20][21]. For the 4 th and 5 th snapshots, testing was supplemented, as volume permitted, by additional Roche (NP total antibody: "Roche-NP") testing at the Providence Health Care Special Chemistry Laboratory.…”

“…As per manufacturer instruction, samples with S/C ratios of <1.00 and ≥1.00 were considered negative or positive, respectively 6. With greater variability, waning and reduced sensitivity for anti-NP overall, especially with the Abbott assay[17][18][19][20][21], orthogonal testing was adjusted to also incorporate the Roche (NP total antibody) assay. For the fourth and fifth sero-surveys, positivity on either Ortho or Abbott assays was followed by Siemens testing per above, but supplemented also by Roche where specimen volume permitted.…”

A case of breakthrough infection with SARS-CoV-2 Delta derivative and reinfection with Omicron variant in a fully vaccinated health care professional

“…A serum sample collected post 8 days re-infection was tested by Anti-SARS-CoV-2 human IgG ELISAs namely, whole virion inactivated antigen, receptor Binding Domain of Spike Protein (S1RBD) specific IgG and Nucleocapsid (N) protein IgG capture ELISA as described earlier 7 .IgG antibody titre was found 1:400, 1:1300 and 1:80 for whole antigen, S1-RBD and N protein ELISA. Although the case had a breakthrough infection followed by a reinfection, the antibody titres were lower than expected.…”

Spike-Receptor Binding Domain (SRBD) Antibodies Secretion in COVID-19 Survivors and Non-Survivors Post-Pre-Endemic Vaccination

“…The significant increase in SRBD antibodies in COVID-19 survivors could be due to memory B cells having recognized antigens from SARS-CoV-2 vision so that when a similar antigen enters the body, the body's immune response will quickly release antibodies. Examination of SRBD antibody levels after vaccination can be one way of monitoring antibody responses in individuals, especially in someone who has a high risk of being exposed (Deshpande et al 2021).…”